Study Summary
This trial is looking at whether a gene variant affects microglial activation and TSPO binding in Alzheimer's disease, and if so, what the consequences are.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Up to 1 year
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
No Cognitive Impairment
1 of 2
Cognitive Impairment
1 of 2
Active Control
Experimental Treatment
250 Total Participants · 2 Treatment Groups
Primary Treatment: 11C-ER176 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What safety measures should be taken when administering 11C-ER176?
"We have rated 11C-ER176 a 2 on our safety scale, as Phase 2 trials typically provide evidence for the former but not the latter." - Anonymous Online Contributor
How many people can participate in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this research study posted on May 11th 2021 is currently recruiting participants. There are 250 spots at a single site for potential patients who meet the criteria." - Anonymous Online Contributor
Is enrollment open to new participants in this research protocol?
"Per clinicaltrials.gov, this medical research is still in need of participants. It was made public on May 11th 2021 and underwent its most recent update on September 15th 2022." - Anonymous Online Contributor